

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following drug types best reflects the mechanism of action of sonrotoclax?
 - Bruton tyrosine kinase (BTK) inhibitor
 - Bcl-2 inhibitor
 - PI3K inhibitor
 - BTK degrader
- Which of the following statements best describes outcomes with fixed-duration first-line acalabrutinib and venetoclax with or without obinutuzumab in the Phase III AMPLIFY trial for patients with CLL?
 - Primary endpoint of improved progression-free survival (PFS) was not met
 - Primary endpoint of improved PFS was met
- Arm D of the Phase III SEQUOIA study demonstrated promising efficacy with the combination of zanubrutinib and venetoclax in which population of patients with treatment-naïve CLL?
 - All comers
 - Those with IGHV-unmutated disease
 - Those with del(17p) and/or TP53 mutations
 - Those with BTK C481S mutations
- What was the approximate reduction in risk of disease progression or death with fixed duration ibrutinib with venetoclax versus chlorambucil with obinutuzumab for previously untreated CLL after extended follow-up of the Phase III GLOW study?
 - 21%
 - 40%
 - 56%
 - 73%
- Which of the following adverse events of special interest in ≥ 5 patients was most commonly observed with nemtabrutinib in the Phase I/II BELLWAVE-001 study for patients with relapsed/refractory CLL/SLL?
 - Oral candidiasis
 - Dizziness
 - Hypertension
 - Peripheral neuropathy